Lilly has completed the acquisition of Sigilon Therapeutics, Inc., a biopharmaceutical company working to develop functional cures for a broad range of acute and chronic diseases, for approximately $34.6 million.   Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. The goal of these therapies is to free patients from constant disease management by sensing blood glucose levels, restoring insulin...